Andere Sprachen Neurogene Inc.

Aktien

A3EX79

US64135M1053

NGNE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
29.87 ^USD	-1.19%		-5.41%	+54.13%

21.03.	NEUROGENE INC. : Bewertung von William Blair & Co. kaufen	ZM
18.03.	Neurogene Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22.04.
North American Morning Briefing : Stocks Struggle After New Records	22.03.
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18.03.
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
North American Morning Briefing : Inflation -2-	15.03.
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04.03.
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04.03.
Neurogene to Participate in Upcoming Investor Conferences	29.02.
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	21.02.
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	17.01.
Neurogene Names Julie Jordan as Chief Medical Officer	16.01.
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16.01.
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16.01.
Neurogene Announces Business Update and 2024 Outlook	05.01.
Neurogene Announces Business Update and 2024 Outlook	05.01.
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	20.12.
Neurogene Completes Merger With Neoleukin Therapeutics	19.12.
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K	19.12.
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	18.12.
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Neurogene Inc.

Aktien

A3EX79

US64135M1053

NGNE

Andere Sprachen

Filter